Insulin Aspart (TP-003CL)

Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. It has a single amino acid substitution at position B28 where proline is replaced with aspartic acid. This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin. Insulin aspart is produced in a genetically modified strain of Saccharomyces cerevisiae and harvested from a bioreactor.      

Protein therapeutics replacing a protein that is deficient or abnormal: Endocrine disorders (hormone deficiencies)
Insulin aspart; insulin glulisine; insulin lispro
Trade Name
Novolog (Aspart), Apidra (Glulisine), Humalog (Lispro)
Insulin analogues with faster onset of action and shorter duration of action
Examples of Clinical Use
Diabetes mellitus
Aspart, Aspart Insulin, B28-Aspart-Insulin, INA-X14, Insulin aspart protamine recombinant, Insulin aspart recombinant, Insulin X14, Insulin, Asp(B28)

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Please input "biolabs"(case insensitive) as verification code.
Contact Us to Order
Tel: 1-631-381-2994
Fax: 1-631-207-8356

45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-381-2994    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2018 Creative-Biolabs All Rights Reserved